Ipamorelin
Selective GH secretagogue with minimal effect on cortisol or prolactin. Reported for sleep and recovery.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Selective GH secretagogue with minimal effect on cortisol or prolactin. Reported for sleep and recovery.
Evidence Intelligence Score™
- Preclinical← current
- Pilot human
- RCT
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data3.8
- Safety maturityFollow-up depth and adverse-event signal2.6
- Mechanism confidencePathway specificity and clarity6.2
- Clinical readinessDistance to physician-prescribable use2.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts4.4
- Long-term dataFollow-up beyond initial trial windows1.8
- Translational confidenceAnimal → human signal preservation4.4
Mechanistic and preclinical evidence is suggestive; controlled human trials are not yet on the index.
Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: speculative. A grade upgrade requires controlled human evidence, not additional preclinical confirmation.
Growth hormone elevation
1 study- weakRaun K, Hansen BS, Johansen NL, et al.
Single IV bolus of ipamorelin (0.5-80 mcg/kg) dose-dependently increased serum GH in healthy volunteers without significant ACTH/cortisol/prolactin elevation. Primarily preclinical paper with small human pilot.
Preclinicaln=81998unreviewed
Growth hormone elevation
1 regimenSelectivity advantage vs other GHS; long-term safety not established.
Single-dose study only; no chronic human dosing trial published.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
2 brands across three tiers.
Compounded (US 503A)
1 brandPatient-specific preparations from US 503A compounding pharmacies. Require a valid prescription, not FDA-approved as finished drugs. Verify the pharmacy's licence and the active ingredient's status on the FDA 503A bulks list.
Research-use only
1 brandSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.